STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators

Grail shares rose 33% on Monday after the FDA posted documents ahead of an advisory committee meeting that suggest the agency may take a favorable view of Galleri, the company’s blood test designed to detect many different types of cancer early, when they can be treated more effectively. The meeting is scheduled for Wednesday and will bring together key experts to discuss the test; investors had already been bidding up Grail’s stock in anticipation of the meeting.

The FDA is not obliged to follow the advice of these advisory panels, but it often does. That makes the Wednesday vote a closely watched signal for Grail, patients, and regulators even though it is not a final approval decision.

Galleri is already available as a laboratory-based diagnostic, but FDA approval would be expected to help lead to reimbursement from Medicare and other insurance payers. The STAT+ article is exclusive to subscribers, with the rest of the story behind a paywall.